New hope for Hard-to-Treat myeloma: targeted combo enters Late-Stage trial
NCT ID NCT06956170
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, pomalidomide, and dexamethasone—works better than a standard combo for people with multiple myeloma that has returned or not responded to treatment. The study involves 21 Japanese adults who have already tried at least one prior therapy. Researchers will measure how long the cancer stays under control and watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody-drug conjugate) combined with pomalidomide and dexamethasone
What this could lead to
If successful, this could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong
This is a small, early-phase study in Japanese patients only, so results may not apply broadly. The drug combination may cause side effects like eye problems or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigation Site
Fukushima, Fukushima, 960-1295, Japan
-
GSK Investigational Site
Nagoya, Aichi-ken, 467-8602, Japan
-
GSK Investigational Site
Kamogawa, Chiba, 296-8602, Japan
-
GSK Investigational Site
Kashiwa, Chiba, 277-8567, Japan
-
GSK Investigational Site
Matsuyama, Ehime, 790-8524, Japan
-
GSK Investigational Site
Maebashi, Gunma, 371-8511, Japan
-
GSK Investigational Site
Shibukawa, Gunma, 377-0280, Japan
-
GSK Investigational Site
Numakunai, Iwate, 028-3695, Japan
-
GSK Investigational Site
Okayama, Okayama-ken, 701-1192, Japan
-
GSK Investigational Site
Osaka, Osaka, 565-0871, Japan
-
GSK Investigational Site
Tottori-shi, Tottori, 683-8504, Japan
-
GSK Investigational Site
Yamagata, Yamagata, 990-9585, Japan
-
GSK Investigational Site
Hokkaido, 060-8648, Japan